Tenax Therapeutics (TENX) Operating Expenses (2010 - 2026)

Tenax Therapeutics (TENX) has 16 years of Operating Expenses data on file, last reported at $16.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 46.17% year-over-year to $16.6 million; the trailing twelve-month figure through Mar 2026 stood at $61.6 million (up 128.87% YoY), and the FY2025 full-year result was $56.4 million, up 189.24% from the prior year.
• Operating Expenses improved to $16.6 million in Q1 2026, from $16.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $16.8 million in Q3 2025 to a low of $1.2 million in Q2 2023.
• A 5-year average of $6.6 million and a median of $3.7 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 88.55% in 2022 and soared 263.84% in 2025, its largest moves.
• Tracing TENX's Operating Expenses over 5 years: stood at $2.6 million in 2022, then jumped by 30.78% to $3.3 million in 2023, then soared by 118.35% to $7.3 million in 2024, then surged by 125.48% to $16.4 million in 2025, then gained by 0.75% to $16.6 million in 2026.
• Business Quant data shows TENX's Operating Expenses at $16.6 million in Q1 2026, $16.4 million in Q4 2025, and $16.8 million in Q3 2025.